Fryer Jeffrey M's Form 4 filing
Rallybio CorpRLYB · filed Jan 11, 2022
- Accession no.
- 0000899243-22-001629
- Filed
- Jan 11, 2022
- Trade date
- Jul 28, 2021-Jan 7, 2022
- Filing delay
- 167 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 8 derivative transactions. Open-market purchases total $94.1K. It was filed 167 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fryer Jeffrey MCIK 0001872879 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 28, 2021 | Common Stock | JOtherAcquired | +32,648 | –F1 | – | 32,648 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherAcquired | +272,609 | –F1 | – | 272,609 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherAcquired | +201,934 | –F1 | – | 201,934 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherAcquired | +201,934 | –F1 | – | 201,934 | Indirect | |
| Jan 7, 2022 | Common Stock | PPurchaseAcquired | +705 | $8.97F6 | +$6,323.85 | 33,353 | Indirect | |
| Jan 7, 2022 | Common Stock | PPurchaseAcquired | +9,295 | $9.44F7 | +$87,744.8 | 42,648 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 28, 2021 | Common Stock | JOtherDisposed | −272,609 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherDisposed | −190,156 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherDisposed | −190,156 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherDisposed | −11,778 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherDisposed | −11,778 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherDisposed | −15,704 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | JOtherDisposed | −16,944 | –F1 | – | 0 | Indirect | |
| Jul 28, 2021 | Common Stock | AGrant or awardAcquired | +160,000 | $0.00 | $0 | 160,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation.
Referenced by the price of 4 transactions in Table I and 7 transactions in Table II.
- F6
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.01 to $9.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $10.00, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Financial Officer & Treasurer